Online inquiry

IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10767MR)

This product GTTS-WQ10767MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR4 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001291980.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2264
UniProt ID P22455
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10767MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5870MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ983MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ15929MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ11400MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ5544MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ13660MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ8420MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ1606MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW